Icosavax to Participate in the Jefferies London Healthcare Conference
Icosavax to Participate in the Jefferies London Healthcare Conference
About IcosavaxSEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK.
西雅图，2023 年 11 月 8 日（GLOBE NEWSWIRE）——生物制药公司 Icosavax, Inc.（纳斯达克股票代码：ICVX）今天宣布，该公司将参加并举办在伦敦杰富瑞医疗保健中心举行的一对一会议会议，将于2023年11月14日至16日在英国伦敦举行。
Jefferies London Healthcare Conference
杰富瑞伦敦医疗保健会议
- Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in London on Wednesday, November 15 at 4:00 pm GMT (11:00 am ET).
- Icosavax首席执行官亚当·辛普森将于格林尼治标准时间11月15日星期三下午4点（美国东部时间上午11点）参加在伦敦举行的炉边谈话。
Interested parties can register for and access the live webcast for this conference by visiting the "Events" section of the Icosavax website. The webcast replay will be available after the conclusion of the presentation.
感兴趣的各方可以通过访问” 注册并访问本次会议的网络直播活动“Icosavax 网站上的栏目。网络直播重播将在演讲结束后播出。
About Icosavax
关于 Icosavax
Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision for combination and pan-respiratory vaccines. Icosavax's VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax's lead program is a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and its pipeline includes additional programs in influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax is located in Seattle.
Icosavax是一家生物制药公司，利用其创新的VLP平台技术开发传染病疫苗，最初的重点是危及生命的呼吸道疾病，愿景是联合疫苗和泛呼吸道疫苗。Icosavax 的 VLP 平台技术旨在实现基于颗粒的多价显示复杂的病毒抗原，它认为这将对目标特定病毒提供广泛、可靠和持久的保护。Icosavax的牵头项目是针对呼吸道合胞病毒（RSV）和人类偏肺病毒（hmPV）的联合候选疫苗，其在研项目包括流感和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的其他项目。Icosavax 成立于 2017 年，旨在推进华盛顿大学蛋白质设计研究所的突破性 VLP 技术，目标是发现、开发和商业化针对传染病的疫苗。Icosavax 位于西雅图。
For more information, visit .
欲了解更多信息，请访问 。
Media Contact:
Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
jessica@litldog.com
858.344.8091
媒体联系人：
杰西卡·英灵博士，
小狗通讯公司
jessica@litldog.com
858.344.8091
Investor Contact:
Laurence Watts
Gilmartin Group, LLC
laurence@gilmartinir.com
619.916.7620
投资者联系人：
劳伦斯·沃茨
吉尔马丁集团有限责任公司
laurence@gilmartinir.com
619.916.7620